One important example is ibrutinib, an orally administered covalent inhibitor of BTK, which had been approved in 2014 for CLL patients who have received at least one previous therapy, and is meanwhile approved for all CLL indications due to its remarkable clinical efficacy [45]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.